Role of Nonalcoholic Fatty Liver Disease As Risk Factor for Drug-induced Hepatotoxicity

Overview

Journal J Clin Transl Res

Date 2017 Jul 11

PMID 28691103

Citations 59

Authors

Julie Massart

Karima Begriche

Caroline Moreau

Bernard Fromenty

Affiliations

Soon will be listed here.

Abstract

Background: Obesity is often associated with nonalcoholic fatty liver disease (NAFLD), which refers to a large spectrum of hepatic lesions including fatty liver, nonalcoholic steatohepatitis (NASH) and cirrhosis. Different investigations showed or suggested that obesity and NAFLD are able to increase the risk of hepatotoxicity of different drugs. Some of these drugs could induce more frequently an acute hepatitis in obese individuals whereas others could worsen pre-existing NAFLD.

Aim: The main objective of the present review was to collect the available information regarding the role of NAFLD as risk factor for drug-induced hepatotoxicity. For this purpose, we performed a data-mining analysis using different queries including drug-induced liver injury (or DILI), drug-induced hepatotoxicity, fatty liver, nonalcoholic fatty liver disease (or NAFLD), steatosis and obesity. The main data from the collected articles are reported in this review and when available, some pathophysiological hypotheses are put forward.

Relevance For Patients: Drugs that could pose a potential risk in obese patients include compounds belonging to different pharmacological classes such as acetaminophen, halothane, methotrexate, rosiglitazone, stavudine and tamoxifen. For some of these drugs, experimental investigations in obese rodents confirmed the clinical observations and unveiled different pathophysiological mechanisms which could explain why these pharmaceuticals are particularly hepatotoxic in obesity and NAFLD. Other drugs such as pentoxifylline, phenobarbital and omeprazole might also pose a risk but more investigations are required to determine whether this risk is significant or not. Because obese people often take several drugs for the treatment of different obesity-related diseases such as type 2 diabetes, hyperlipidemia and coronary heart disease, it is urgent to identify the main pharmaceuticals that can cause acute hepatitis on a fatty liver background or induce NAFLD worsening.

Citing Articles

Turmeric-induced Liver Injury.

Alghzawi F, Jones R, Haas C J Community Hosp Intern Med Perspect. 2024; 14(3):55-59.

PMID: 39036565 PMC: 11259472. DOI: 10.55729/2000-9666.1332.

Complex dichotomous links of nonalcoholic fatty liver disease and inflammatory bowel disease: exploring risks, mechanisms, and management modalities.

Aggarwal K, Singh B, Goel A, Agrawal D, Bansal S, Kanagala S Intest Res. 2024; 22(4):414-427.

PMID: 38835139 PMC: 11534450. DOI: 10.5217/ir.2024.00001.

Drug-Induced Fatty Liver Disease (DIFLD): A Comprehensive Analysis of Clinical, Biochemical, and Histopathological Data for Mechanisms Identification and Consistency with Current Adverse Outcome Pathways.

Lopez-Pascual E, Rienda I, Perez-Rojas J, Rapisarda A, Garcia-Llorens G, Jover R Int J Mol Sci. 2024; 25(10).

PMID: 38791241 PMC: 11121209. DOI: 10.3390/ijms25105203.

NAFLD Fibrosis Progression and Type 2 Diabetes: The Hepatic-Metabolic Interplay.

Cernea S Life (Basel). 2024; 14(2).

PMID: 38398781 PMC: 10890557. DOI: 10.3390/life14020272.

Serine synthesis via reversed SHMT2 activity drives glycine depletion and acetaminophen hepatotoxicity in MASLD.

Ghrayeb A, Finney A, Agranovich B, Peled D, Anand S, McKinney M Cell Metab. 2024; 36(1):116-129.e7.

PMID: 38171331 PMC: 10777734. DOI: 10.1016/j.cmet.2023.12.013.

References

Takamura T, Shimizu A, Komura T, Ando H, Zen Y, Minato H . Selective estrogen receptor modulator raloxifene-associated aggravation of nonalcoholic steatohepatitis. Intern Med. 2007; 46(9):579-81. DOI: 10.2169/internalmedicine.46.6374. View

Koppe S, Sahai A, Malladi P, Whitington P, Green R . Pentoxifylline attenuates steatohepatitis induced by the methionine choline deficient diet. J Hepatol. 2004; 41(4):592-8. DOI: 10.1016/j.jhep.2004.06.030. View

Labbe G, Fromenty B, Freneaux E, Morzelle V, Letteron P, Berson A . Effects of various tetracycline derivatives on in vitro and in vivo beta-oxidation of fatty acids, egress of triglycerides from the liver, accumulation of hepatic triglycerides, and mortality in mice. Biochem Pharmacol. 1991; 41(4):638-41. DOI: 10.1016/0006-2952(91)90640-q. View

Schattenberg J, Wang Y, Singh R, Rigoli R, Czaja M . Hepatocyte CYP2E1 overexpression and steatohepatitis lead to impaired hepatic insulin signaling. J Biol Chem. 2005; 280(11):9887-94. DOI: 10.1074/jbc.M410310200. View

Sudano I, Flammer A, Periat D, Enseleit F, Hermann M, Wolfrum M . Acetaminophen increases blood pressure in patients with coronary artery disease. Circulation. 2010; 122(18):1789-96. DOI: 10.1161/CIRCULATIONAHA.110.956490. View

Garcia-Ruiz I, Solis-Munoz P, Fernandez-Moreira D, Munoz-Yague T, Solis-Herruzo J . In vitro treatment of HepG2 cells with saturated fatty acids reproduces mitochondrial dysfunction found in nonalcoholic steatohepatitis. Dis Model Mech. 2014; 8(2):183-91. PMC: 4314783. DOI: 10.1242/dmm.018234. View

Lebrecht D, Vargas-Infante Y, Setzer B, Kirschner J, Walker U . Uridine supplementation antagonizes zalcitabine-induced microvesicular steatohepatitis in mice. Hepatology. 2006; 45(1):72-9. DOI: 10.1002/hep.21490. View

Zhang L, Ging N, Komoda T, Hanada T, Suzuki T, Watanabe K . Antibiotic susceptibility of mammalian mitochondrial translation. FEBS Lett. 2005; 579(28):6423-7. DOI: 10.1016/j.febslet.2005.09.103. View

Aubert J, Begriche K, Knockaert L, Robin M, Fromenty B . Increased expression of cytochrome P450 2E1 in nonalcoholic fatty liver disease: mechanisms and pathophysiological role. Clin Res Hepatol Gastroenterol. 2011; 35(10):630-7. DOI: 10.1016/j.clinre.2011.04.015. View

10.

West S . Methotrexate hepatotoxicity. Rheum Dis Clin North Am. 1997; 23(4):883-915. DOI: 10.1016/s0889-857x(05)70365-3. View

11.

Hartman J, Martin H, Caro A, Pearce A, Miller G . Subcellular localization of rat CYP2E1 impacts metabolic efficiency toward common substrates. Toxicology. 2015; 338:47-58. PMC: 4658230. DOI: 10.1016/j.tox.2015.10.001. View

12.

Kohlroser J, Mathai J, Reichheld J, Banner B, Bonkovsky H . Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration. Am J Gastroenterol. 2000; 95(1):272-6. DOI: 10.1111/j.1572-0241.2000.01707.x. View

13.

Dansette P, Bonierbale E, Minoletti C, Beaune P, Pessayre D, Mansuy D . Drug-induced immunotoxicity. Eur J Drug Metab Pharmacokinet. 1999; 23(4):443-51. DOI: 10.1007/BF03189993. View

14.

Biour M, Ben Salem C, Chazouilleres O, Grange J, Serfaty L, Poupon R . [Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs]. Gastroenterol Clin Biol. 2005; 28(8-9):720-59. DOI: 10.1016/s0399-8320(04)95062-2. View

15.

Stine J, Chalasani N . Chronic liver injury induced by drugs: a systematic review. Liver Int. 2015; 35(11):2343-53. DOI: 10.1111/liv.12958. View

16.

Kinugawa H, Kawahara M, Amakata Y, Maeda T . Halothane-induced cytotoxicity in isolated rat hepatocytes: an electron microscopic study. In Vivo. 1993; 7(6A):497-501. View

17.

de Waal R, Cohen K, Maartens G . Systematic review of antiretroviral-associated lipodystrophy: lipoatrophy, but not central fat gain, is an antiretroviral adverse drug reaction. PLoS One. 2013; 8(5):e63623. PMC: 3665842. DOI: 10.1371/journal.pone.0063623. View

18.

Chalasani N, Aljadhey H, Kesterson J, Murray M, Hall S . Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology. 2004; 126(5):1287-92. DOI: 10.1053/j.gastro.2004.02.015. View

19.

Claridge L, Eksteen B, Smith A, Shah T, Holt A . Acute liver failure after administration of paracetamol at the maximum recommended daily dose in adults. BMJ. 2010; 341:c6764. DOI: 10.1136/bmj.c6764. View

20.

Zong H, Armoni M, Harel C, Karnieli E, Pessin J . Cytochrome P-450 CYP2E1 knockout mice are protected against high-fat diet-induced obesity and insulin resistance. Am J Physiol Endocrinol Metab. 2011; 302(5):E532-9. PMC: 3311288. DOI: 10.1152/ajpendo.00258.2011. View